BOTHELL, WA (December 9, 2024) –  VerAvanti, seeks to become the foremost provider of cutting-edge, single use endoscopy solutions, striving to improve global healthcare by enhancing both diagnostic precision and treatment effectiveness to help physicians find answers to treat strokes and heart attacks that often strike without warning, today announced an expansion of their executive team as preparation for submission to the FDA.

Jason Capodanno has been promoted to Chief Operating Officer responsible for overseeing daily activities with a focus of enhancing operational efficiency and achieving strategic goals. Mr. Capodanno’s is a Biomechanical Engineer with 20+ years of experience over primarily 4 companies and 4 disciplines: Class III PMA, Class II 510k, Surgical Tools Class I/II and Biotechnology. Companies include multinational medical conglomerates with highly procedural driven processes to mid-cap medical device companies going through growing pains and start-up environments where funding was dependent on milestone executions.

Juan Vegarra has joined the team as Chief Marketing Officer, responsible for building and executing marketing strategies to drive brand awareness, product adoption, and market growth on a global basis. Mr. Vegarra has more than 30 years of experience in global business development. A visionary and passionate leader with a proven track record of executing successful sales and marketing campaigns, developing strategic partnerships, and raising capital across diverse and competitive industries.

David Goesling has joined the team as Chief Financial Officer, responsible for the financial strategy and management, ensuring the company's fiscal health and supporting growth. Mr. Goesling, a senior financial executive with extensive startup/growth phase experience in both private and publicly traded corporations who enjoys building leading edge technology companies.

Gerald McMorrow, founder and CEO comments: “The expansion of the executive team is part of the planned evolution as the company prepares for manufacturing start up, FDA clearance and market entry. The team at VerAvanti looks forward to providing new “Vascular Eyes” to Interventionalists. We are proud to be a part of the continued evolution of the  Interventional Cardiology miracle”.

About VerAvanti

Founded in 2013, privately held VerAvanti is pioneering a modular platform designed to advance imaging and therapeutic capabilities.  The company’s flagship product Scanning Fiber Endoscope (SaFE), harnesses the accuracy and versatility of laser technology to deliver superior video imaging to help physicians close treatment gaps and proactively identify interventions for the 200,000 individuals (U.S.) who suffer ischemic strokes due to an unknown cause1.

Protected by more than 50 patents, the SaFE is a micro-imaging catheter equipped with an extreme depth of focus camera that provides physicians a previously unseen surgical view into hidden intravascular anatomy, enabling more proactive diagnosis and treatment of individuals at-risk for stroke and cardiovascular events. Visit VerAvanti to learn more and review scientific papers and SaFE images.

Media Inquiries:

Gabriela Vega

VerAvanti Director of Marketing

gabriela.vega@veravanti.com

(425) 201-6070

Visit us on social media

www.veravanti.com

VerAvanti Inc - LinkedIn